<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839341</url>
  </required_header>
  <id_info>
    <org_study_id>APL-106-01</org_study_id>
    <nct_id>NCT04839341</nct_id>
  </id_info>
  <brief_title>Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients</brief_title>
  <official_title>A Phase I, Open-labeled Multicenter Study to Determine Pharmacokinetics, Safety, Tolerability and Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apollomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang CrownMab Biotech Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Apollomics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific&#xD;
      E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in&#xD;
      combination with chemotherapy to treat Chinese relapsed/refractory AML patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter open-labelled study conducted in subjects with relapsed or&#xD;
      refractory AML in China. The study includes the following phases: screening phase, induction&#xD;
      phase, consolidation phase baseline, consolidation phase and follow-up period.&#xD;
&#xD;
      Screening phase:&#xD;
&#xD;
      This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing&#xD;
      the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML.&#xD;
      Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject&#xD;
      must be obtained before screening.&#xD;
&#xD;
      Baseline period:&#xD;
&#xD;
      The baseline period is 1 day before study drug administration.&#xD;
&#xD;
      Induction treatment:&#xD;
&#xD;
      During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment&#xD;
      and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen)&#xD;
      chemotherapy.&#xD;
&#xD;
      Consolidation baseline:&#xD;
&#xD;
      The baseline of the consolidation phase is 1 day before the treatment administration of the&#xD;
      consolidation phase.&#xD;
&#xD;
      Consolidation treatment:&#xD;
&#xD;
      Subjects who met the criteria for consolidation treatment started the consolidation period at&#xD;
      the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.&#xD;
&#xD;
      Follow-up period:&#xD;
&#xD;
      Each subject should complete the following follow-up stage: (1) Response evaluation to&#xD;
      determine remission to the induction treatment (induction period); (2) EOT assessment after&#xD;
      completing the last consolidation treatment cycle; (3) Death. Survival and long-term&#xD;
      follow-up, including initiation of new anti-leukemia treatment (within 6 months after the&#xD;
      last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14&#xD;
      days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The&#xD;
      longest survival follow-up time is 3 years (calculated from the start of treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Tmax)</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the pharmacokinetic profile in patients with relapsed/refractory AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the pharmacokinetic profile in patients with relapsed/refractory AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the pharmacokinetic profile in patients with relapsed/refractory AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the pharmacokinetic profile in patients with relapsed/refractory AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Incidence of Adverse Events</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants with an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The tolerance of participants with relapsed/refractory AML.</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants could tolerate the Uproleselan combined with chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the period from when the subject receives the first dose of the study drug to death from any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate (rate of CR, CR/CRi and CR/CRh)</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTCAE grade 3 and 4 oral mucositis</measure>
    <time_frame>Up to 254 days</time_frame>
    <description>The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapsed/Refractory AML</condition>
  <arm_group>
    <arm_group_label>A Phase I, open-labeled multicenter study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uproleselan</intervention_name>
    <description>A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin</description>
    <arm_group_label>A Phase I, open-labeled multicenter study</arm_group_label>
    <other_name>GMI-1271</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Key Criteria:&#xD;
&#xD;
          1. ≥18 years and ≤60 years in age&#xD;
&#xD;
          2. AML (including secondary AML) diagnosed as per WHO standards (2008).&#xD;
&#xD;
          3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied&#xD;
             repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be&#xD;
             applied Venatoclax /hypomethylation drug [HMA] can be used before and after&#xD;
             chemotherapy.&#xD;
&#xD;
               1. For relapse AML, it must be the first or second relapse, and remain untreated.&#xD;
&#xD;
               2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3&#xD;
                  inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted&#xD;
                  inhibitors used alone are not considered cytotoxic chemotherapy are allowed.&#xD;
&#xD;
          4. ECOG performance status score is 0 to 2.&#xD;
&#xD;
          5. Stable hemodynamics and good organ function and good organ function.&#xD;
&#xD;
        Exclusion key Criteria:&#xD;
&#xD;
          1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage&#xD;
             (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or&#xD;
             secondary refractory AML.&#xD;
&#xD;
          2. Active signs or symptoms of CNS involvement by malignancy.&#xD;
&#xD;
          3. Stem cell transplantation ≤4 months prior to dosing.&#xD;
&#xD;
          4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other&#xD;
             experimental therapy or chemotherapy within 14 days of dosing.&#xD;
&#xD;
          5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.&#xD;
&#xD;
          6. Inadequate organ function.&#xD;
&#xD;
          7. Abnormal liver function.&#xD;
&#xD;
          8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.&#xD;
&#xD;
          9. Moderate kidney dysfunction (glomerular filtration rate &lt;45 mL/min).&#xD;
&#xD;
         10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.&#xD;
&#xD;
         11. Clinically significant cardiovascular disease.&#xD;
&#xD;
         12. Major surgery within 4 weeks of dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhejiang CrownMab Ltd.</last_name>
    <phone>0571-83521933</phone>
    <email>ClinicalTrialsChina@apollomicsinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Li</last_name>
    <phone>0571-83521933</phone>
    <email>Qian.li@apollomicsinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxiang Wang, Phd</last_name>
      <phone>022-23909120</phone>
      <email>wangjx@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, PhD</last_name>
      <phone>057187236685</phone>
      <email>jiej0503@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

